Xenon Pharmaceuticals Management

How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


Ian Mortimer (46 yo)





Mr. Ian C. Mortimer, M.B.A, C.P.A, C.M.A., has been the Chief Executive Officer and Director at Xenon Pharmaceuticals Inc. since June 03, 2021. He has been Director at Perimeter Medical Imaging AI, Inc. si...

CEO Compensation Analysis

Ian Mortimer's Compensation vs Xenon Pharmaceuticals Earnings
How has Ian Mortimer's remuneration changed compared to Xenon Pharmaceuticals's earnings?
DateTotal Comp.SalaryCompany Earnings
Jun 30 2022n/an/a


Mar 31 2022n/an/a


Dec 31 2021US$4mUS$524k


Sep 30 2021n/an/a


Jun 30 2021n/an/a


Mar 31 2021n/an/a


Dec 31 2020US$2mUS$462k


Sep 30 2020n/an/a


Jun 30 2020n/an/a


Mar 31 2020n/an/a


Dec 31 2019US$2mUS$421k


Sep 30 2019n/an/a


Jun 30 2019n/an/a


Mar 31 2019n/an/a


Dec 31 2018US$923kUS$342k


Sep 30 2018n/an/a


Jun 30 2018n/an/a


Mar 31 2018n/an/a


Dec 31 2017US$945kUS$312k


Sep 30 2017n/an/a


Jun 30 2017n/an/a


Mar 31 2017n/an/a


Dec 31 2016US$555kUS$261k


Sep 30 2016n/an/a


Jun 30 2016n/an/a


Mar 31 2016n/an/a


Dec 31 2015US$1mUS$256k


Compensation vs Market: Ian's total compensation ($USD3.89M) is about average for companies of similar size in the US market ($USD5.48M).

Compensation vs Earnings: Ian's compensation has increased whilst the company is unprofitable.

Leadership Team

Experienced Management: XENE's management team is considered experienced (2.2 years average tenure).

Board Members

Experienced Board: XENE's board of directors are considered experienced (6.8 years average tenure).